In this webinar, you will learn:
- Workflows for antibody characterization that extend beyond the primary amino acid sequence
- How to leverage HDX-MS for epitope mapping and SPR for binding kinetics to understand the mechanism of action and maximize the effectiveness of your characterization efforts
- How to ensure high-quality antibody production with in-depth post-translational modification analysis and sequence variant analysis
- About maintaining product purity and regulatory compliance with host-cell protein analysis
Abstract
Overlooking the intricacies of antibody characterization beyond the antibody sequence leads to unanticipated challenges during downstream development and IND submissions. Potential concerns may emerge related to production quality, including post-translational modifications (PTMs), sequence variants, and cell culture contaminants. As such, in-depth antibody characterization is best conducted early and often in the developmental pipeline.
What are the necessary steps to ensure the development of high-quality antibodies?
The initial steps involve elucidating the primary amino acid sequence of the antibody, pinpointing its binding site on the antigen, as well as its binding kinetics. Prior to advancing to preclinical testing, it is essential to assess the quality and purity of the generated antibodies. This often entails PTM and in-depth glycan analysis, identifying sequence variants, and conducting host-cell protein analysis.
In this webinar, we explore mass spectrometry-based techniques designed for complete antibody characterization. We walk through a streamlined workflow for total antibody characterization, which includes understanding the structure and function of the antibody, to evaluating the overall quality of antibody production.
Speaker Bios
Kyle Annibale
Rapid Novor
Scientific Sales Representative – Canada
Kyle looks to utilize his understanding of biotechnology and innovation to help clients across Canada achieve their goals in preclinical research. Being with Rapid Novor for over 2 years has allowed him to understand industry themes, pain points, and connect with like minded individuals globally. Driven by his passion for pushing the boundaries of proteomics, Kyle is dedicated to fostering collaborative partnerships that drive innovation and accelerate scientific progress in the field of antibody sequencing.
Hugo Gagnon, PhD
Allumiqs
Chief Scientific Officer
Hugo is the Chief Scientific Officer of Allumiqs. Previously, he served as the CEO and co-founder of PhenoSwitch Bioscience, which was acquired by Allumiqs in 2022.
Hugo studied at Université de Sherbrooke, where he earned a B.Sc. in biochemistry, M.Sc. in Pharmacology, and a Ph.D. in biochemistry. During his Ph.D Hugo used mass spectrometry through different collaborations and core facility services to answer biological questions. He quickly learned that access to mass spectrometry was far from simple, requiring considerable resource investment to obtain desirable results, and subsequently built a team of omics and mass spec experts to address this specific need.
Related Posts
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics